Amy S. Chappell

Dr. Amy S. Chappell is an accomplished biotech pharmaceutical executive and neuroscientist with experience across all phases of preclinical and clinical drug development. Prior to joining the pharmaceutical industry, Dr. Chappell was on the neurology faculty at the Indiana University Medical Center (IUMC). Her career in the pharma began at Eli Lilly and Company, where she worked as the lead physician on numerous projects and product teams, developing clinical plans and protocols for a broad range of CNS conditions. During her time at Lilly, she also spearheaded the development of registration phase protocols of duloxetine (Cymbalta) for fibromyalgia, osteoarthritis, and chronic low back pain, all of which resulted in FDA approvals.

Following her 25 years at Lilly, Dr. Chappell consulted for Convergence Pharma and Biogen. In 2017, she took on the role of Vice President, Neuroscience for Pharmaceutical Product Development (PPD), a contract research organization. She began consulting for Eliem, Inc. in 2019, and was soon hired as the Chief Medical Officer, playing an instrumental role in the success of Eliem’s IPO in 2022. She continued to see patients part-time throughout her entire pharmaceutical career.

Dr. Chappell graduated from Antioch College and the Indiana University School of Medicine (IUMC). She completed 2 years of a pediatrics residency and an epilepsy fellowship at the Johns Hopkins Hospital Medical Center as well as a neurology residency at IUMC. She is board certified in neurology with special competencies in both child neurology and lifestyle medicine and holds an active Florida medical license.